Phase I Study of Dasatinib in Combination With Ipilimumab for Patients With Advanced Gastrointestinal Stromal Tumor and Other Sarcomas

Trial Profile

Phase I Study of Dasatinib in Combination With Ipilimumab for Patients With Advanced Gastrointestinal Stromal Tumor and Other Sarcomas

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Dasatinib (Primary) ; Ipilimumab (Primary)
  • Indications Chondrosarcoma; Clear cell sarcoma; Ewing's sarcoma; Gastrointestinal stromal tumours; Osteosarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 22 Dec 2016 Results assessing safety and efficacy published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top